Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published October 2020 | Supplemental Material
Journal Article Open

Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 Mediator kinases

Abstract

Pluripotent stem cells (PSCs) transition between cell states in vitro, reflecting developmental changes in the early embryo. PSCs can be stabilized in the naive state by blocking extracellular differentiation stimuli, particularly FGF–MEK signalling. Here, we report that multiple features of the naive state in human and mouse PSCs can be recapitulated without affecting FGF–MEK signalling or global DNA methylation. Mechanistically, chemical inhibition of CDK8 and CDK19 (hereafter CDK8/19) kinases removes their ability to repress the Mediator complex at enhancers. CDK8/19 inhibition therefore increases Mediator-driven recruitment of RNA polymerase II (RNA Pol II) to promoters and enhancers. This efficiently stabilizes the naive transcriptional program and confers resistance to enhancer perturbation by BRD4 inhibition. Moreover, naive pluripotency during embryonic development coincides with a reduction in CDK8/19. We conclude that global hyperactivation of enhancers drives naive pluripotency, and this can be achieved in vitro by inhibiting CDK8/19 kinase activity. These principles may apply to other contexts of cellular plasticity.

Additional Information

© 2020 Nature Publishing Group. Received 02 May 2019. Accepted 07 August 2020. Published 28 September 2020. We thank A. Smith, T. MacFarlan, Z. Izsvák, M. Ko, J. Hanna, D. Grégoire and U. Hibner for gifts of reagents; N. Prats and L. César Fernández for assistance, as well as staff at the CNIO and IRB core facilities. M.N.S. was funded by a Leverhulme Trust early career fellowship. Work in the laboratory of M.Z.-G. was funded by the Wellcome Trust (098287/Z/12/Z) and the European Research Council (ERC) (669198). I.C. was funded by the Secretaria d'Universitats i Recerca de la Generalitat de Catalunya and European Social Fund. I.A. and P.S. were supported by the Fondation pour la Recherche Medicale (DEQ20170336757), Infrastructure Nationale en Biologie et Santé INGESTEM (ANR-11-INBS-0009), IHU-B CESAME (ANR-10-IBHU-003), LabEx REVIVE (ANR-10-LABX-73), LabEx DEVweCAN (ANR-10-LABX-0061) and LabEx CORTEX (ANR-11-LABX-0042) of University of Lyon within the programme 'Investissements d'Avenir' (ANR-11-IDEX-0007). Research by J.P., S.M. and C.B.-A. was supported in part by a grant from the Spanish Ministry of Economy and Competitiveness (SAF2013-44267-R) and by the CNIO. Work in the laboratory of D.F. was funded by the Institut National du Cancer (PLBIO10-068 and PLBIO15-005) and the Ligue National Contre le Cancer (EL2018.LNCC/DF). Work in the laboratory of N.M. was funded by the ERC, under the European Union Horizon 2020 research and innovation programme (StG-2014–640525_REGMAMKID), the Spanish Association Against Cancer (AECC/LABAE16006), Carlos III Health Institute (Red TerCel, CardioCel, RD16/0011/0027), Ministry of Economy and Competitiveness (MINECO) projects SAF2017–89782-R, SAF2015–72617-EXP and RYC-2014–16242, and the CERCA/Government of Catalonia (2017 SGR 1306). Work in the laboratory of S.O. was funded by SAF2013–44866-R from MINECO Spain. Work in the laboratory of M.F.F. was funded by Plan Nacional de I+D+I 2013–2016/FEDER (PI15/00892, to M.F.F. and A.F.F.); the ISCIII-Subdireccion General de Evaluación y Fomento de la Investigación and Plan Nacional de I+D+I 2008–2011/FEDER (CP11/00131, to A.F.F.); IUOPA (to M.I.S.); and the Asturias Regional Government (GRUPIN14–052, to M.F.F.). The IUOPA is supported by the Obra Social Liberbank-Cajastur, Spain. Work in the laboratory of M.S. was funded by the CNIO, the IRB and by grants from Spanish Ministry of Economy co-funded by the European Regional Development Fund (SAF2017-82613-R), ERC (ERC-2014-AdG/669622), Botin Foundation, Banco Santander (Santander Universities Global Division), laCaixa Foundation and Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Data availability. RNA-seq and ChIP–seq data are available from the GEO database under accession numbers GSE112208 and GSE127186. The MS proteomics data are available from the ProteomeXchange Consortium/PRIDE repository under the dataset identifier PXD009200. Details on the published datasets used in Fig. 4e,k are provided in Supplementary Table 3. All other data supporting the findings of this study are available from the corresponding author on reasonable request. Source data are provided with this paper. Author Contributions. C.J.L. designed and performed most of the experiments with mouse cells and embryos, contributed to bioinformatics data analysis and cowrote the manuscript. R.B. designed and performed most of the experiments with human cells, and provided general experimental support. A.M.-V. performed proteomic and bioinformatics analysis. M.N.S. performed embryo experiments, immunofluorescence and data analysis. S.N.-P., I.C., L.R.-G., N.A. and M.M.-M. contributed to experimental work and data analysis. C.T. and E.G. contributed to research with human PSCs and performed differentiation, immunofluorescence and confocal analysis of these experiments, supervised by N.M.; O.G.-C., G.G.-L. and C.S.-O.A., contributed to bioinformatics analyses. C.B.-A., S.M. and J.P. selected, synthesized and characterized small-molecule inhibitors. S.O. provided reagents, contributed to experimental design and supervised mouse embryo research. I.A. and P.S. performed human–rabbit interspecies chimaera and STAT3 assays. S.P., E.S., A.C. and D.F. generated the CDK8-KO mouse, provided reagents and performed additional inhibitor analyses. A.F.F., M.I.S. and M.F.F. performed DNA methylation analysis. P.S., D.F., J.M. and M.Z.-G. provided reagents, discussion and revisions. M.S. designed and supervised the study, secured funding, analysed the data and cowrote the manuscript. All of the authors discussed the results and commented on the manuscript. The authors declare no competing interests.

Attached Files

Supplemental Material - 41556_2020_573_Fig10_ESM.jpg

Supplemental Material - 41556_2020_573_Fig11_ESM.jpg

Supplemental Material - 41556_2020_573_Fig12_ESM.jpg

Supplemental Material - 41556_2020_573_Fig13_ESM.jpg

Supplemental Material - 41556_2020_573_Fig14_ESM.jpg

Supplemental Material - 41556_2020_573_Fig15_ESM.jpg

Supplemental Material - 41556_2020_573_Fig16_ESM.jpg

Supplemental Material - 41556_2020_573_Fig17_ESM.jpg

Supplemental Material - 41556_2020_573_Fig18_ESM.jpg

Supplemental Material - 41556_2020_573_Fig9_ESM.jpg

Supplemental Material - 41556_2020_573_MOESM10_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM11_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM12_ESM.pdf

Supplemental Material - 41556_2020_573_MOESM13_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM14_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM15_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM16_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM17_ESM.pdf

Supplemental Material - 41556_2020_573_MOESM18_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM19_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM1_ESM.pdf

Supplemental Material - 41556_2020_573_MOESM20_ESM.pdf

Supplemental Material - 41556_2020_573_MOESM21_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM22_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM23_ESM.pdf

Supplemental Material - 41556_2020_573_MOESM24_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM25_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM26_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM27_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM28_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM29_ESM.pdf

Supplemental Material - 41556_2020_573_MOESM2_ESM.pdf

Supplemental Material - 41556_2020_573_MOESM3_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM4_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM5_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM6_ESM.pdf

Supplemental Material - 41556_2020_573_MOESM7_ESM.xlsx

Supplemental Material - 41556_2020_573_MOESM8_ESM.pdf

Supplemental Material - 41556_2020_573_MOESM9_ESM.xlsx

Files

41556_2020_573_Fig12_ESM.jpg
Files (119.6 MB)
Name Size Download all
md5:3327ce7257a52dd9b52de1666d231dd1
668.9 kB Preview Download
md5:bbe6428998a9a72d234e9a911310a035
296.9 kB Preview Download
md5:e51aa6b5dcd13811cf20081697014b36
23.1 kB Download
md5:eaf7f4ae49451d07a7d0564adb3657f7
420.6 kB Preview Download
md5:6b1447b03659f92b953ba52611f31eb5
519.2 kB Download
md5:514235ec4db5edd72d45f6c635ce16c4
151.0 kB Download
md5:15e2e5ee75daffefc7346cea2f717718
530.4 kB Preview Download
md5:75f5a98cbd7d4a7993c99f4e3364547d
18.8 kB Download
md5:79a8968bb10996da89718b50c7b3a94c
6.4 MB Preview Download
md5:ad0f32b7e36548d26156c9eb876af00d
72.6 kB Download
md5:046613bded1441666fa4d615b2f03bfb
367.3 kB Preview Download
md5:ec7d08545c3efa1f8a1768d1216db8ce
45.9 kB Download
md5:ebc629f17fe394e6ccb139eef0671804
392.2 kB Preview Download
md5:5af0fe6e9126fd681ce3194df876ae02
454.2 kB Preview Download
md5:c3ef6770116d43a582cfd89235c09347
539.2 kB Preview Download
md5:f394ee89191e6723621ab708cdb7c487
11.0 MB Download
md5:a89449cbf3a724fe3d6900c787043fda
8.8 MB Download
md5:b995fc3e0d23e4c7c249792a5ec1c348
8.1 MB Download
md5:d9b7676c90b51a702d791ea2986a3fc4
231.7 kB Preview Download
md5:12b8661e352b4d7d39b4f842bc90d411
305.7 kB Preview Download
md5:67552e17d5e4f5cc1311b51d06535fb6
1.1 MB Download
md5:0eeb82e9d58d22e3add7102bbcc6f66b
38.5 MB Download
md5:986fcc3105690841179713bbf61ec47b
2.4 MB Preview Download
md5:3fb3bc97fa838b6e33a07a7af3ab6561
1.2 MB Download
md5:82def3a642fa536216ff6a11ed005dd3
27.5 MB Download
md5:467b97773f4ddf8f13fb691c802cdbcd
628.5 kB Preview Download
md5:2cbbe948eb6be84e824918f3daa0ec7f
419.9 kB Preview Download
md5:8b88f8aaffedc4ca7951acd0822fdbd0
4.1 MB Download
md5:80a82915ad66ee4e814259ec1d2a3280
570.9 kB Preview Download
md5:faab8d073bab9aef7f4289cb91b4affd
494.0 kB Preview Download
md5:6d7cb29fbd156d9d555232d97fc324ca
1.6 MB Download
md5:d58593d4f52a3441d987f62f76c4c23e
596.8 kB Preview Download
md5:5f9c0306ddfe5847ef86bff1741740b0
34.4 kB Download
md5:f25b8d094ab532c97deea6cfa0836f69
253.5 kB Preview Download
md5:e364ee37fae0ca2eb0c18bdd6703d182
686.5 kB Preview Download
md5:a1dc7fdac6819f240ee10d813cea7d73
32.5 kB Download
md5:fcd5f3b54aeafa99c6cd4c32ca37c64f
172.5 kB Download
md5:d4cc041111412e81ebd434a073b11244
34.0 kB Download
md5:203ee447bb15ed83e2bf17264e934908
22.2 kB Download

Additional details

Created:
August 19, 2023
Modified:
December 22, 2023